nnpNeurology, Neuropsychiatry, PsychosomaticsНеврология, нейропсихиатрия, психосоматика2074-27112310-1342"IMA-Press", LLC10.14412/2074-2711-2022-6-122-130nnp-1931Research ArticleREVIEWSОБЗОРЫOn the use of chondroitin sulfate, glucosamine sulfate and undenatured type II collagen for back and limb pain and osteoarthritisО применении хондроитина сульфата, глюкозамина сульфата и неденатурированного коллагена II типа при боли в спине и конечностях и при остеоартритеhttps://orcid.org/0000-0002-7663-710XГромоваО. А.GromovaO. A.

Ольга Алексеевна Громова

119333, Москва, ул. Вавилова, 44, корп. 2

Olga Alekseevna Gromova

119333, Moscow, Vavilov Str., 44, Build. 2

unesco.gromova@gmail.comhttps://orcid.org/0000-0002-2659-7998ТоршинИ. Ю.TorshinI. Y.

119333, Москва, ул. Вавилова, 44, корп. 2

119333, Moscow, Vavilov Str., 44, Build. 2

https://orcid.org/0000-0002-6068-3080ЛилаА. М.LilaA. M.

115522, Москва, Каширское шоссе, 34А125993, Москва, ул. Баррикадная, 2/1, стр. 1

115522, Moscow, Kashirskoe Shosse, 34A125993, Moscow, Barrikadnaya Str., 2/1, Build. 1

Институт фармакоинформатики Федерального исследовательского центра «Информатика и управление» Российской академии наукРоссияInstitute of Pharmacoinformatics of the Federal Research Center “Computer Science and Management”, Russian Academy of SciencesRussian FederationФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой»; кафедра ревматологии ФГБОУ ДПО «Российская медицинская академия непрерывного профессионального образования» Минздрава РоссииРоссияV.A. Nasonova Research Institute of Rheumatology; Department of Rheumatology, Russian Medical Academy of Continuing Professional EducationRussian Federation202219122022146122130Copyright © Gromova O.A., Torshin I.Y., Lila A.M., 20222022Громова О.А., Торшин И.Ю., Лила А.М.Gromova O.A., Torshin I.Y., Lila A.M.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://nnp.ima-press.net/nnp/article/view/1931

Backpain and pain in the limbs are often associate with the destruction of the cartilage and bone tissue of the joint, which affects the nerve terminals and leads to an exacerbation of pain symptoms (as happens, for example, in osteoarthritis). As a result, pain relief without protection and reconstruction of cartilage (chondroprotection), will be symptomatic. The chondroprotective effects of glucosamine sulfate (GS), chondroitin sulfate (CS) and undenatured type II collagen (UC-II) have different molecular mechanisms. Therefore, with the combined use of CS, GS and UC-II per os, different mechanisms of action of individual components will complement each other, increasing the effectiveness of pain pharmacotherapy.

Боль в спине и конечностях зачастую может быть связана с деструкцией хрящевой и костной ткани сустава, что затрагивает нервные окончания и приводит к обострению болевой симптоматики (как это происходит, например, при остеоартрите). Вследствие этого без защиты и реконструкции хряща (хондропротекции) купирование болевого синдрома будет носить симптоматический характер. Хондропротекторные эффекты глюкозамина сульфата (ГС), хондроитина сульфата (ХС) и неденатурированного коллагена II типа (НК-II) осуществляются по разным молекулярным механизмам. Поэтому при сочетанном применении ХС, ГС и НК-II per os разные механизмы действия отдельных компонентов будут дополнять друг друга, повышая эффективность фармакотерапии боли.

больостеоартритхондроитина сульфатглюкозамина сульфатнеденатурированный коллаген II типаХондрогард Триоpainosteoarthritischondroitin sulfateglucosamine sulfateundenatured type II collagenChondrogard TrioСтатья опубликована при поддержке компании ЗАО «ФармФирма «Сотекс».Publication of this article has been supported by Sotex PharmFirma.ReferencesГромова ОА, Торшин ИЮ, Семенов ВА. О неврологических ролях хондроитина сульфата и глюкозамина сульфата: систематический анализ. Неврология, нейропсихиатрия, психосоматика. 2019;11(3):137-43. doi:10.14412/2074-2711-2019-3-137-143Gromova OA, Torshin IYu, Semenov VA. On the neurological roles of chondroitin sulfate and glucosamine sulfate: a systematic analysis. Nevrologiya, neiropsikhiatriya, psikhosomatika = Neurology, Neuropsychiatry, Psychosomatics. 2019;11(3):137-43. doi:10.14412/2074-2711-2019-3-137-143 (In Russ.).Торшин ИЮ, Громова ОА, Лила АМ, Лиманова ОА. Систематический анализ молекулярной патофизиологии тендовагинита: перспективность применения хондроитина сульфата и глюкозамина сульфата. Неврология, нейропсихиатрия, психосоматика. 2020;12(2):64-71. doi:10.14412/2074-2711-2020-2-64-71Torshin IYu, Gromova OA, Lila AM, Limanova OA. Systematic analysis of the molecular pathophysiology of tenosynovitis: promise for using chondroitin sulfate and glucosamine sulfate. Nevrologiya, neiropsikhiatriya, psikhosomatika = Neurology, Neuropsychiatry, Psychosomatics. 2020;12(2):64-71. doi:10.14412/2074-2711-2020-2-64-71 (In Russ.).Торшин ИЮ, Лила АМ, Наумов АВ и др. Метаанализ клинических исследований эффективности лечения остеоартита препаратом Хондрогард. ФАРМАКОЭКОНОМИКА. Современная фармакоэкономика и фармакоэпидемиология. 2020;13(4):18-29. doi:10.17749/2070-4909/farmakoekonomika.2020.066Torshin IYu, Lila AM, Naumov AV, et al. Meta-analysis of clinical trials of osteoarthritis treatment effectiveness with Chondroguard. FARMAKOEKONOMIKA. Sovremennaya farmakoekonomika i farmakoepidemiologiya = FARMAKOEKONOMIKA. Modern Pharmacoeconomics and Pharmacoepidemiology. 2020;13(4):18-29. doi:10.17749/2070-4909/farmakoekonomika.2020.066 (In Russ.).Honvo G, Bruyere O, Geerinck A, et al. Efficacy of Chondroitin Sulfate in Patients with Knee Osteoarthritis: A Comprehensive Meta-Analysis Exploring Inconsistencies in Randomized, Placebo-Controlled Trials. Adv Ther. 2019 May;36(5):1085-99. doi:10.1007/s12325-019-00921-wHonvo G, Bruyere O, Geerinck A, et al. Efficacy of Chondroitin Sulfate in Patients with Knee Osteoarthritis: A Comprehensive Meta-Analysis Exploring Inconsistencies in Randomized, Placebo-Controlled Trials. Adv Ther. 2019 May;36(5):1085-99. doi:10.1007/s12325-019-00921-wГромова ОА, Торшин ИЮ, Лила АМ, Шавловская ОА. О перспективах использования неденатурированного коллагена II типа в терапии остеоартрита и других заболеваний суставов. Современная ревматология. 2022;16(4):111-6. doi:10.14412/1996-7012-2022-4-111-116Gromova OA, Torshin IYu, Lila AM, Shavlovskaya OA. On the prospects for the use of undenatured type II collagen in the treatment of osteoarthritis and other joint diseases. Sovremennaya Revmatologiya=Modern Rheumatology Journal. 2022;16(4):111-6. doi:10.14412/1996-7012-2022-4-111-116 (In Russ.).Лила АМ, Громова ОА, Торшин ИЮ. Молекулярные эффекты хондрогарда при остеоартрите и грыжах межпозвоночного диска. Неврология, нейропсихиатрия, психосоматика. 2017;9(3):88-97. doi:10.14412/2074-2711-2017-3-88-97Lila AM, Gromova OA, Torshin IYu. Molecular effects of chondroguard in osteoarthritis and herniated discs. Nevrologiya, neiropsikhiatriya, psikhosomatika = Neurology, Neuropsychiatry, Psychosomatics. 2017;9(3):88-97. doi:10.14412/2074-2711-2017-3-88-9 (In Russ.).Volpi N. Anti-inflammatory activity of chondroitin sulphate: new functions from an old natural macromolecule. Inflammopharmacology 2011;19(6):299-306. doi:10.1007/s10787-011-0098-0. Epub 2011 Nov 1.Volpi N. Anti-inflammatory activity of chondroitin sulphate: new functions from an old natural macromolecule. Inflammopharmacology 2011;19(6):299-306. doi:10.1007/s10787-011-0098-0. Epub 2011 Nov 1.Pecchi E, Priam S, Mladenovic Z, et al. A potential role of chondroitin sulfate on bone in osteoarthritis: inhibition of prostaglandin E2 and matrix metalloproteinases synthesis in interleukin-1β-stimulated osteoblasts. Osteoarthritis Cartilage. 2012 Feb;20(2):127-35. doi:10.1016/j.joca.2011.12.002Pecchi E, Priam S, Mladenovic Z, et al. A potential role of chondroitin sulfate on bone in osteoarthritis: inhibition of prostaglandin E2 and matrix metalloproteinases synthesis in interleukin-1β-stimulated osteoblasts. Osteoarthritis Cartilage. 2012 Feb;20(2):127-35. doi:10.1016/j.joca.2011.12.002Harada H, Takahashi M. CD44-dependent intracellular and extracellular catabolism of hyaluronic acid by hyaluronidase-1 and -2. J Biol Chem. 2007 Feb 23;282(8):5597-607. doi:10.1074/jbc.M608358200Harada H, Takahashi M. CD44-dependent intracellular and extracellular catabolism of hyaluronic acid by hyaluronidase-1 and -2. J Biol Chem. 2007 Feb 23;282(8):5597-607. doi:10.1074/jbc.M608358200Meyer K, Hoffman P, Linker A. Hyaluronidases. In: Boyer PD, Lardy H, Myrback K (eds). The Enzymes. 2<sup>nd</sup> ed. Vol. 4. New York: Academic Press; 1960.Meyer K, Hoffman P, Linker A. Hyaluronidases. In: Boyer PD, Lardy H, Myrback K (eds). The Enzymes. 2<sup>nd</sup> ed. Vol. 4. New York: Academic Press; 1960.Silva C, Novoa-Carballal R, Reis RL, Pashkuleva I. Following the enzymatic digestion of chondroitin sulfate by a simple GPC analysis. Anal Chim Acta. 2015 Jul 23;885:207-13. doi:10.1016/j.aca.2015.05.034. Epub 2015 Jun 6.Silva C, Novoa-Carballal R, Reis RL, Pashkuleva I. Following the enzymatic digestion of chondroitin sulfate by a simple GPC analysis. Anal Chim Acta. 2015 Jul 23;885:207-13. doi:10.1016/j.aca.2015.05.034. Epub 2015 Jun 6.Knudson W, Gundlach MW, Schmid TM, Conrad HE. Selective hydrolysis of chondroitin sulfates by hyaluronidase. Biochemistry. 1984 Jan 17;23(2):368-75. doi:10.1021/bi00297a028Knudson W, Gundlach MW, Schmid TM, Conrad HE. Selective hydrolysis of chondroitin sulfates by hyaluronidase. Biochemistry. 1984 Jan 17;23(2):368-75. doi:10.1021/bi00297a028Calamia V, Ruiz-Romero C, Rocha B, et al. Pharmacoproteomic study of the effects of chondroitin and glucosamine sulfate on human articular chondrocytes. Arthritis Res Ther. 2010;12(4):R138. doi:10.1186/ar3077Calamia V, Ruiz-Romero C, Rocha B, et al. Pharmacoproteomic study of the effects of chondroitin and glucosamine sulfate on human articular chondrocytes. Arthritis Res Ther. 2010;12(4):R138. doi:10.1186/ar3077Navarro SL, White E, Kantor ED, et al. Randomized trial of glucosamine and chondroitin supplementation on inflammation and oxidative stress biomarkers and plasma proteomics profiles in healthy humans. PLoS One. 2015 Feb 26;10(2):e0117534. doi:10.1371/journal.pone.0117534Navarro SL, White E, Kantor ED, et al. Randomized trial of glucosamine and chondroitin supplementation on inflammation and oxidative stress biomarkers and plasma proteomics profiles in healthy humans. PLoS One. 2015 Feb 26;10(2):e0117534. doi:10.1371/journal.pone.0117534Calamia V, Mateos J, Fernandez-Puente P, Blanco FJ. A pharmacoproteomic study confirms the synergistic effect of chondroitin sulfate and glucosamine. Sci Rep. 2014 Jun 10;4:5069. doi:10.1038/srep05069Calamia V, Mateos J, Fernandez-Puente P, Blanco FJ. A pharmacoproteomic study confirms the synergistic effect of chondroitin sulfate and glucosamine. Sci Rep. 2014 Jun 10;4:5069. doi:10.1038/srep05069Conte A, Volpi N, Palmieri L, et al. Biochemical and pharmacokinetic aspects of oral treatment with chondroitin sulfate. Arzneimittelforschung. 1995 Aug;45(8):918-25.Conte A, Volpi N, Palmieri L, et al. Biochemical and pharmacokinetic aspects of oral treatment with chondroitin sulfate. Arzneimittelforschung. 1995 Aug;45(8):918-25.Торшин ИЮ, Лила АМ, Громова ОА. Гепатопротекторные эффекты хондроитина сульфата и глюкозамина сульфата. ФАРМАКОЭКОНОМИКА. Современная фармакоэкономика и фармакоэпидемиология. 2021;14(4):515-25. doi:10.17749/2070-4909/farmakoekonomika.2021.112Torshin IYu, Lila AM, Gromova OA. Hepatoprotective effects of chondroitin sulfate and glucosamine sulfate. FARMAKOEKONOMIKA. Sovremennaya farmakoekonomika i farmakoepidemiologiya = FARMAKOEKONOMIKA. Modern Pharmacoeconomics and Pharmacoepidemiology. 2021;14(4):515-25. doi:10.17749/2070-4909/farmakoekonomika.2021.112 (In Russ.).Торшин ИЮ, Лила АМ, Лиманова ОА, Громова ОА. Перспективы применения хондроитина сульфата и глюкозамина сульфата при остеоартрите в сочетании с патологией почек и мочевыделительной системы. ФАРМАКОЭКОНОМИКА. Современная фармакоэкономика и фармакоэпидемиология. 2020;13(1):23-34. doi:10.17749/2070-4909.2020.13.1.23-34Torshin IYu, Lila AM, Limanova OA, Gromova OA. Prospects for the use of chondroitin sulfate and glucosamine sulfate with osteoarthritis associated with pathology of the kidneys and urinary system. FARMAKOEKONOMIKA. Sovremennaya farmakoekonomika i farmakoepidemiologiya = FARMAKOEKONOMIKA. Modern Pharmacoeconomics and Pharmacoepidemiology. 2020;13(1):23-34. doi:10.17749/2070-4909.2020.13.1.23-34 (In Russ.).Ibanez-Sanz G, Diez-Villanueva A, Vilorio-Marques L, Moreno V. Possible role of chondroitin sulphate and glucosamine for primary prevention of colorectal cancer. Results from the MCC-Spain study. Sci Rep. 2018 Feb 1;8(1):2040. doi:10.1038/s41598-018-20349-6Ibanez-Sanz G, Diez-Villanueva A, Vilorio-Marques L, Moreno V. Possible role of chondroitin sulphate and glucosamine for primary prevention of colorectal cancer. Results from the MCC-Spain study. Sci Rep. 2018 Feb 1;8(1):2040. doi:10.1038/s41598-018-20349-6Von Felden J, Montani M, Kessebohm K, Stickel F. Drug-induced acute liver injury mimicking autoimmune hepatitis after intake of dietary supplements containing glucosamine and chondroitin sulfate. Int J Clin Pharmacol Ther. 2013 Mar;51(3):219-23. doi:10.5414/CP201835Von Felden J, Montani M, Kessebohm K, Stickel F. Drug-induced acute liver injury mimicking autoimmune hepatitis after intake of dietary supplements containing glucosamine and chondroitin sulfate. Int J Clin Pharmacol Ther. 2013 Mar;51(3):219-23. doi:10.5414/CP201835Calamia V, Fernandez-Puente P, Mateos J, et al. Pharmacoproteomic study of three different chondroitin sulfate compounds on intracellular and extracellular human chondrocyte proteomes. Mol Cell Proteomics. 2012 Jun;11(6):M111.013417. doi:10.1074/mcp.M111.013417Calamia V, Fernandez-Puente P, Mateos J, et al. Pharmacoproteomic study of three different chondroitin sulfate compounds on intracellular and extracellular human chondrocyte proteomes. Mol Cell Proteomics. 2012 Jun;11(6):M111.013417. doi:10.1074/mcp.M111.013417Громова ОА, Торшин ИЮ, Зайчик БЦ и др. О различиях в стандартизации лекарственных препаратов на основе экстрактов хондроитина сульфата. ФАРМАКОЭКОНОМИКА. Современная фармакоэкономика и фармакоэпидемиология. 2021;14(1):40-52. doi:10.17749/2070-4909/farmakoekonomika.2021.083Gromova OA, Torshin IYu, Zaychik BTs, et al. Differences in the standardization of medicinal products based on extracts of chondroitin sulfate. FARMAKOEKONOMIKA. Sovremennaya farmakoekonomika i farmakoepidemiologiya = FARMAKOEKONOMIKA. Modern Pharmacoeconomics and Pharmacoepidemiology. 2021;14(1):50-62. doi:10.17749/2070-4909/farmakoekonomika.2021.083 (In Russ.).Volpi N. Quality of different chondroitin sulfate preparations in relation to their therapeutic activity. J Pharm Pharmacol. 2009 Oct;61(10):1271-80. doi:10.1211/jpp/61.10.0002Volpi N. Quality of different chondroitin sulfate preparations in relation to their therapeutic activity. J Pharm Pharmacol. 2009 Oct;61(10):1271-80. doi:10.1211/jpp/61.10.0002Pelletier JP, Raynauld JP, Beaulieu AD, et al. Chondroitin sulfate efficacy versus celecoxib on knee osteoarthritis structural changes using magnetic resonance imaging: a 2-year multicentre exploratory study. Arthritis Res Ther. 2016 Nov 3;18(1):256. doi:10.1186/s13075-016-1149-0Pelletier JP, Raynauld JP, Beaulieu AD, et al. Chondroitin sulfate efficacy versus celecoxib on knee osteoarthritis structural changes using magnetic resonance imaging: a 2-year multicentre exploratory study. Arthritis Res Ther. 2016 Nov 3;18(1):256. doi:10.1186/s13075-016-1149-0Linares PM, Chaparro M, Algaba A, et al. Effect of Chondroitin Sulphate on Pro-Inflammatory Mediators and Disease Activity in Patients with Inflammatory Bowel Disease. Digestion. 2015;92(4):203-10. doi:10.1159/000439522Linares PM, Chaparro M, Algaba A, et al. Effect of Chondroitin Sulphate on Pro-Inflammatory Mediators and Disease Activity in Patients with Inflammatory Bowel Disease. Digestion. 2015;92(4):203-10. doi:10.1159/000439522Verges J, Montell E, Herrero M, et al. Clinical and histopathological improvement of psoriasis with oral chondroitin sulfate: a serendipitous finding. Dermatol Online J. 2005 Mar 1;11(1):31.Verges J, Montell E, Herrero M, et al. Clinical and histopathological improvement of psoriasis with oral chondroitin sulfate: a serendipitous finding. Dermatol Online J. 2005 Mar 1;11(1):31.Volpi N. Oral absorption and bioavailability of ichthyic origin chondroitin sulfate in healthy male volunteers. Osteoarthritis Cartilage. 2003 Jun;11(6):433-41. doi:10.1016/s1063-4584(03)00051-7Volpi N. Oral absorption and bioavailability of ichthyic origin chondroitin sulfate in healthy male volunteers. Osteoarthritis Cartilage. 2003 Jun;11(6):433-41. doi:10.1016/s1063-4584(03)00051-7Volpi N, Mantovani V, Galeotti F, et al. Oral Bioavailability and Pharmacokinetics of Nonanimal Chondroitin Sulfate and Its Constituents in Healthy Male Volunteers. Clin Pharmacol Drug Dev. 2019 Apr;8(3):336-45. doi:10.1002/cpdd.587Volpi N, Mantovani V, Galeotti F, et al. Oral Bioavailability and Pharmacokinetics of Nonanimal Chondroitin Sulfate and Its Constituents in Healthy Male Volunteers. Clin Pharmacol Drug Dev. 2019 Apr;8(3):336-45. doi:10.1002/cpdd.587Volpi N. Oral bioavailability of chondroitin sulfate (Condrosulf) and its constituents in healthy male volunteers. Osteoarthritis Cartilage. 2002 Oct;10(10):768-77. doi:10.1053/joca.2002.0824Volpi N. Oral bioavailability of chondroitin sulfate (Condrosulf) and its constituents in healthy male volunteers. Osteoarthritis Cartilage. 2002 Oct;10(10):768-77. doi:10.1053/joca.2002.0824Wei CY, Liao NB, Zhang Y, et al. In vitro fermentation behaviors of fucosylated chondroitin sulfate from Pearsonothuria graeffei by human gut microflora. Int J Biol Macromol. 2017 Sep;102:1195-201. doi:10.1016/j.ijbiomac.2017.04.036Wei CY, Liao NB, Zhang Y, et al. In vitro fermentation behaviors of fucosylated chondroitin sulfate from Pearsonothuria graeffei by human gut microflora. Int J Biol Macromol. 2017 Sep;102:1195-201. doi:10.1016/j.ijbiomac.2017.04.036Торшин ИЮ, Громова ОА, Нечаева ГИ и др. Систематический анализ молекулярно-биологических механизмов поддержки хондроитина сульфатом метаболизма соединительной ткани. Неврология, нейропсихиатрия, психосоматика. 2021;13(1):154-62. doi:10.14412/2074-2711-2021-1-154-162Torshin IYu, Gromova OA, Nechaeva GI, et al. Systematic analysis of molecular biological mechanisms for supporting connective tissue metabolism with chondroitin sulfate. Nevrologiya, neiropsikhiatriya, psikhosomatika = Neurology, Neuropsychiatry, Psychosomatics. 2021;13(1):154-62. doi:10.14412/2074-2711-2021-1-154-162 (In Russ.).Торшин ИЮ, Громова ОА, Лила АМ и др. Толл-подобные рецепторы как компонент патофизиологии остеоартрита: противовоспалительное, анальгетическое и нейропротекторное действие. Неврология, нейропсихиатрия, психосоматика. 2021;13(4):123-9. doi:10.14412/2074-2711-2021-4-123-129Torshin IYu, Gromova OA, Lila AM, et al. Toll-like receptors as a part of osteoarthritis pathophysiology: anti-inflammatory, analgesic and neuroprotective effects. Nevrologiya, neiropsikhiatriya, psikhosomatika = Neurology, Neuropsychiatry, Psychosomatics. 2021;13(4):123-9. doi:10.14412/2074-2711-2021-4-123-129 (In Russ.).Zhu X, Wu D, Sang L, et al. Comparative effectiveness of glucosamine, chondroitin, acetaminophen or celecoxib for the treatment of knee and/or hip osteoarthritis: a network meta-analysis. Clin Exp Rheumatol. 2018 JulAug;36(4):595-602. Epub 2018 Jan 31.Zhu X, Wu D, Sang L, et al. Comparative effectiveness of glucosamine, chondroitin, acetaminophen or celecoxib for the treatment of knee and/or hip osteoarthritis: a network meta-analysis. Clin Exp Rheumatol. 2018 JulAug;36(4):595-602. Epub 2018 Jan 31.Громова ОА, Торшин ИЮ, Лила АМ, Громов АН. Молекулярные механизмы глюкозамина сульфата при лечении дегенеративно-дистрофических заболеваний суставов и позвоночника: результаты протеомного анализа. Неврология, нейропсихиатрия, психосоматика. 2018;10(2):38-44. doi:10.14412/2074-2711-2018-2-38-44Gromova OA, Torshin IYu, Lila AM, Gromov AN. Molecular mechanisms of action of glucosamine sulfate in the treatment of degenerative-dystrophic diseases of the joints and spine: results of proteomic analysis. Nevrologiya, neiropsikhiatriya, psikhosomatika = Neurology, neuropsychiatry, psychosomatics. 2018;10(2):38-44. doi:10.14412/2074-2711-2018-2-38-44 (In Russ.).Mammone T, Gan D, Fthenakis C, Marenus K. The effect of N-acetyl-glucosamine on stratum corneum desquamation and water content in human skin. J Cosmet Sci. 2009 JulAug;60(4):423-8.Mammone T, Gan D, Fthenakis C, Marenus K. The effect of N-acetyl-glucosamine on stratum corneum desquamation and water content in human skin. J Cosmet Sci. 2009 JulAug;60(4):423-8.Kantor ED, Lampe JW, Navarro SL, et al. Associations between glucosamine and chondroitin supplement use and biomarkers of systemic inflammation. J Altern Complement Med. 2014 Jun;20(6):479-85. doi:10.1089/acm.2013.0323. Epub 2014 Apr 16.Kantor ED, Lampe JW, Navarro SL, et al. Associations between glucosamine and chondroitin supplement use and biomarkers of systemic inflammation. J Altern Complement Med. 2014 Jun;20(6):479-85. doi:10.1089/acm.2013.0323. Epub 2014 Apr 16.Yang L, Li FF, Han YC, et al. Cannabinoid receptor CB2 is involved in tetrahydrocannabinol-induced anti-inflammation against lipopolysaccharide in MG-63 cells. Mediators Inflamm. 2015;2015:362126. doi:10.1155/2015/362126Yang L, Li FF, Han YC, et al. Cannabinoid receptor CB2 is involved in tetrahydrocannabinol-induced anti-inflammation against lipopolysaccharide in MG-63 cells. Mediators Inflamm. 2015;2015:362126. doi:10.1155/2015/362126Kim MM, Mendis E, Rajapakse N, Kim SK. Glucosamine sulfate promotes osteoblastic differentiation of MG-63 cells via anti-inflammatory effect. Bioorg Med Chem Lett. 2007 Apr 1;17(7):1938-42. doi:10.1016/j.bmcl.2007.01.030Kim MM, Mendis E, Rajapakse N, Kim SK. Glucosamine sulfate promotes osteoblastic differentiation of MG-63 cells via anti-inflammatory effect. Bioorg Med Chem Lett. 2007 Apr 1;17(7):1938-42. doi:10.1016/j.bmcl.2007.01.030Largo R, Alvarez-Soria MA, Diez-Ortego I, et al. Glucosamine inhibits IL-1beta-induced NFkappaB activation in human osteoarthritic chondrocytes. Osteoarthritis Cartilage. 2003 Apr;11(4):290-8. doi:10.1016/s1063-4584(03)00028-1Largo R, Alvarez-Soria MA, Diez-Ortego I, et al. Glucosamine inhibits IL-1beta-induced NFkappaB activation in human osteoarthritic chondrocytes. Osteoarthritis Cartilage. 2003 Apr;11(4):290-8. doi:10.1016/s1063-4584(03)00028-1Basak M, Joseph S, Joshi S, Sawant S. Comparative bioavailability of a novel timed release and powder-filled glucosamine sulfate formulation – a multi-dose, randomized, crossover study. Int J Clin Pharmacol Ther. 2004 Nov;42(11):597-601. doi:10.5414/cpp42597Basak M, Joseph S, Joshi S, Sawant S. Comparative bioavailability of a novel timed release and powder-filled glucosamine sulfate formulation – a multi-dose, randomized, crossover study. Int J Clin Pharmacol Ther. 2004 Nov;42(11):597-601. doi:10.5414/cpp42597Persiani S, Roda E, Rovati LC, et al. Glucosamine oral bioavailability and plasma pharmacokinetics after increasing doses of crystalline glucosamine sulfate in man. Osteoarthritis Cartilage. 2005 Dec;13(12):1041-9. doi:10.1016/j.joca.2005.07.009Persiani S, Roda E, Rovati LC, et al. Glucosamine oral bioavailability and plasma pharmacokinetics after increasing doses of crystalline glucosamine sulfate in man. Osteoarthritis Cartilage. 2005 Dec;13(12):1041-9. doi:10.1016/j.joca.2005.07.009Kantor ED, Lampe JW, Vaughan TL, et al. Association between use of specialty dietary supplements and C-reactive protein concentrations. Am J Epidemiol. 2012 Dec 1;176(11):1002-13. doi:10.1093/aje/kws186. Epub 2012 Nov 8.Kantor ED, Lampe JW, Vaughan TL, et al. Association between use of specialty dietary supplements and C-reactive protein concentrations. Am J Epidemiol. 2012 Dec 1;176(11):1002-13. doi:10.1093/aje/kws186. Epub 2012 Nov 8.Lee YH, Woo JH, Choi SJ, et al. Effect of glucosamine or chondroitin sulfate on the osteoarthritis progression: a meta-analysis. Rheumatol Int. 2010 Jan;30(3):357-63. doi:10.1007/s00296-009-0969-5Lee YH, Woo JH, Choi SJ, et al. Effect of glucosamine or chondroitin sulfate on the osteoarthritis progression: a meta-analysis. Rheumatol Int. 2010 Jan;30(3):357-63. doi:10.1007/s00296-009-0969-5Wu D, Huang Y, Gu Y, Fan W. Efficacies of different preparations of glucosamine for the treatment of osteoarthritis: a metaanalysis of randomised, double-blind, placebocontrolled trials. Int J Clin Pract. 2013 Jun;67(6):585-94. doi:10.1111/ijcp.12115Wu D, Huang Y, Gu Y, Fan W. Efficacies of different preparations of glucosamine for the treatment of osteoarthritis: a metaanalysis of randomised, double-blind, placebocontrolled trials. Int J Clin Pract. 2013 Jun;67(6):585-94. doi:10.1111/ijcp.12115Hochberg MC, Martel-Pelletier J, Monfort J, et al; MOVES Investigation Group. Combined chondroitin sulfate and glucosamine for painful knee osteoarthritis: a multicentre, randomised, double-blind, non-inferiority trial versus celecoxib. Ann Rheum Dis. 2016 Jan;75(1):37-44. doi:10.1136/annrheumdis2014-206792Hochberg MC, Martel-Pelletier J, Monfort J, et al; MOVES Investigation Group. Combined chondroitin sulfate and glucosamine for painful knee osteoarthritis: a multicentre, randomised, double-blind, non-inferiority trial versus celecoxib. Ann Rheum Dis. 2016 Jan;75(1):37-44. doi:10.1136/annrheumdis2014-206792Zotkin EG, Kharitonova TV, Shkireeva SIu. [Clinical use of chondroitin sulfate in patients with osteoarthritis in geriatric practice]. Adv Gerontol. 2014;27(2):366-375.Zotkin EG, Kharitonova TV, Shkireeva SIu. [Clinical use of chondroitin sulfate in patients with osteoarthritis in geriatric practice]. Adv Gerontol. 2014;27(2):366-375.Borisenko OV, Belen'kii DA. [Impact of combined therapy using glucosamine sulfate and anti-inflammatory agent on pain severity in patients with osteoarthritis: prospective, non-controlled postmarketing study]. Klin Med (Mosk). 2013;91(5):65-71 (In Russ.).Borisenko OV, Belen'kii DA. [Impact of combined therapy using glucosamine sulfate and anti-inflammatory agent on pain severity in patients with osteoarthritis: prospective, non-controlled postmarketing study]. Klin Med (Mosk). 2013;91(5):65-71 (In Russ.).Торшин ИЮ, Громова ОА, Лила АМ. О перспективах применения хондроитина сульфата и глюкозамина сульфата в терапии пациентов с остеоартритом на фоне ожирения (метаболического синдрома). ФАРМАКОЭКОНОМИКА. Современная фармакоэкономика и фармакоэпидемиология. 2022;15(3):390-401. doi:10.17749/2070-4909/farmakoekonomika.2022.145Torshin IYu, Gromova OA, Lila AM. Prospects for the use of chondroitin sulfate and glucosamine sulfate in the treatment of patients with obesity-associated osteoarthritis (metabolic syndrome). FARMAKOEKONOMIKA. Sovremennaya farmakoekonomika i farmakoepidemiologiya = FARMAKOEKONOMIKA. Modern Pharmacoeconomics and Pharmacoepidemiology. 2022;15(3):390-401. doi:10.17749/2070-4909/farmakoekonomika.2022.145 (In Russ.).Chan PS, Caron JP, Rosa GJ, Orth MW. Glucosamine and chondroitin sulfate regulate gene expression and synthesis of nitric oxide and prostaglandin E(2) in articular cartilage explants. Osteoarthritis Cartilage. 2005 May;13(5):387-94. doi:10.1016/j.joca.2005.01.003Chan PS, Caron JP, Rosa GJ, Orth MW. Glucosamine and chondroitin sulfate regulate gene expression and synthesis of nitric oxide and prostaglandin E(2) in articular cartilage explants. Osteoarthritis Cartilage. 2005 May;13(5):387-94. doi:10.1016/j.joca.2005.01.003Bruyere O, Altman RD, Reginster JY. Efficacy and safety of glucosamine sulfate in the management of osteoarthritis: Evidence from real-life setting trials and surveys. Semin Arthritis Rheum. 2016 Feb;45(4 Suppl):S12-7. doi:10.1016/j.semarthrit.2015.11.011Bruyere O, Altman RD, Reginster JY. Efficacy and safety of glucosamine sulfate in the management of osteoarthritis: Evidence from real-life setting trials and surveys. Semin Arthritis Rheum. 2016 Feb;45(4 Suppl):S12-7. doi:10.1016/j.semarthrit.2015.11.011Runhaar J, Deroisy R, van Middelkoop M, et al. The role of diet and exercise and of glucosamine sulfate in the prevention of knee osteoarthritis: Further results from the PRevention of knee Osteoarthritis in Overweight Females (PROOF) study. Semin Arthritis Rheum. 2016 Feb;45(4 Suppl):S42-8. doi:10.1016/j.semarthrit.2015.11.001Runhaar J, Deroisy R, van Middelkoop M, et al. The role of diet and exercise and of glucosamine sulfate in the prevention of knee osteoarthritis: Further results from the PRevention of knee Osteoarthritis in Overweight Females (PROOF) study. Semin Arthritis Rheum. 2016 Feb;45(4 Suppl):S42-8. doi:10.1016/j.semarthrit.2015.11.001Klatt AR, Paul-Klausch B, Klinger G, et al. A critical role for collagen II in cartilage matrix degradation: collagen II induces pro-inflammatory cytokines and MMPs in primary human chondrocytes. J Orthop Res. 2009 Jan;27(1):65-70. doi:10.1002/jor.20716Klatt AR, Paul-Klausch B, Klinger G, et al. A critical role for collagen II in cartilage matrix degradation: collagen II induces pro-inflammatory cytokines and MMPs in primary human chondrocytes. J Orthop Res. 2009 Jan;27(1):65-70. doi:10.1002/jor.20716Bagchi D, Misner B, Bagchi M, et al. Effects of orally administered undenatured type II collagen against arthritic inflammatory diseases: a mechanistic exploration. Int J Clin Pharmacol Res. 2002;22(3-4):101-10.Bagchi D, Misner B, Bagchi M, et al. Effects of orally administered undenatured type II collagen against arthritic inflammatory diseases: a mechanistic exploration. Int J Clin Pharmacol Res. 2002;22(3-4):101-10.Carafoli F, Bihan D, Stathopoulos S, et al. Crystallographic insight into collagen recognition by discoidin domain receptor 2. Structure. 2009 Dec 9;17(12):1573-81. doi:10.1016/j.str.2009.10.012Carafoli F, Bihan D, Stathopoulos S, et al. Crystallographic insight into collagen recognition by discoidin domain receptor 2. Structure. 2009 Dec 9;17(12):1573-81. doi:10.1016/j.str.2009.10.012Vogel WF, Abdulhussein R, Ford CE. Sensing extracellular matrix: an update on discoidin domain receptor function. Cell Signal. 2006;18(8):1108-16. doi:10.1016/j.cellsig.2006.02.012. Epub 2006 Feb 28.Vogel WF, Abdulhussein R, Ford CE. Sensing extracellular matrix: an update on discoidin domain receptor function. Cell Signal. 2006;18(8):1108-16. doi:10.1016/j.cellsig.2006.02.012. Epub 2006 Feb 28.Seo MC, Kim S, Kim SH, et al. Discoidin domain receptor 1 mediates collagen-induced inflammatory activation of microglia in culture. J Neurosci Res. 2008 Apr;86(5):1087-95. doi:10.1002/jnr.21552Seo MC, Kim S, Kim SH, et al. Discoidin domain receptor 1 mediates collagen-induced inflammatory activation of microglia in culture. J Neurosci Res. 2008 Apr;86(5):1087-95. doi:10.1002/jnr.21552Yoshinari O, Moriyama H, Shiojima Y. An overview of a novel, water-soluble undenatured type II collagen (NEXT-II). J Am Coll Nutr. 2015;34(3):255-62. doi:10.1080/07315724.2014.919541Yoshinari O, Moriyama H, Shiojima Y. An overview of a novel, water-soluble undenatured type II collagen (NEXT-II). J Am Coll Nutr. 2015;34(3):255-62. doi:10.1080/07315724.2014.919541Sahin K, Kucuk O, Orhan C, et al. Niacinamide and undenatured type II collagen modulates the inflammatory response in rats with monoiodoacetate-induced osteoarthritis. Sci Rep. 2021 Jul 19;11(1):14724. doi:10.1038/s41598-021-94142-3Sahin K, Kucuk O, Orhan C, et al. Niacinamide and undenatured type II collagen modulates the inflammatory response in rats with monoiodoacetate-induced osteoarthritis. Sci Rep. 2021 Jul 19;11(1):14724. doi:10.1038/s41598-021-94142-3Orhan C, Juturu V, Sahin E, et al. Undenatured Type II Collagen Ameliorates Inflammatory Responses and Articular Cartilage Damage in the Rat Model of Osteoarthritis. Front Vet Sci. 2021 Mar 4;8:617789. doi:10.3389/fvets.2021.617789Orhan C, Juturu V, Sahin E, et al. Undenatured Type II Collagen Ameliorates Inflammatory Responses and Articular Cartilage Damage in the Rat Model of Osteoarthritis. Front Vet Sci. 2021 Mar 4;8:617789. doi:10.3389/fvets.2021.617789Bakilan F, Armagan O, Ozgen M, et al. Effects of Native Type II Collagen Treatment on Knee Osteoarthritis: A Randomized Controlled Trial. Eurasian J Med. 2016 Jun;48(2):95-101. doi:10.5152/eurasianjmed.2015.15030Bakilan F, Armagan O, Ozgen M, et al. Effects of Native Type II Collagen Treatment on Knee Osteoarthritis: A Randomized Controlled Trial. Eurasian J Med. 2016 Jun;48(2):95-101. doi:10.5152/eurasianjmed.2015.15030Lugo JP, Saiyed ZM, Lane NE. Efficacy and tolerability of an undenatured type II collagen supplement in modulating knee osteoarthritis symptoms: a randomized, double-blind, placebo-controlled study. Nutr J. 2016;15:14. doi:10.1186/s12937-016-0130-8Lugo JP, Saiyed ZM, Lane NE. Efficacy and tolerability of an undenatured type II collagen supplement in modulating knee osteoarthritis symptoms: a randomized, double-blind, placebo-controlled study. Nutr J. 2016;15:14. doi:10.1186/s12937-016-0130-8Garcia-Coronado JM, Martinez-Olvera L, Simental-Mendia M. Effect of collagen supplementation on osteoarthritis symptoms: a meta-analysis of randomized placebo-controlled trials. Int Orthop. 2019 Mar;43(3):531-8. doi:10.1007/s00264-018-4211-5Garcia-Coronado JM, Martinez-Olvera L, Simental-Mendia M. Effect of collagen supplementation on osteoarthritis symptoms: a meta-analysis of randomized placebo-controlled trials. Int Orthop. 2019 Mar;43(3):531-8. doi:10.1007/s00264-018-4211-5Yoshinari O, Marone PA, Moriyama H, et al. Safety and toxicological evaluation of a novel, water-soluble undenatured type II collagen. Toxicol Mech Methods. 2013 Sep;23(7):491-9. doi:10.3109/15376516.2013.781255Yoshinari O, Marone PA, Moriyama H, et al. Safety and toxicological evaluation of a novel, water-soluble undenatured type II collagen. Toxicol Mech Methods. 2013 Sep;23(7):491-9. doi:10.3109/15376516.2013.781255Marone PA, Lau FC, Gupta RC, et al. Safety and toxicological evaluation of undenatured type II collagen. Toxicol Mech Methods. 2010 May;20(4):175-89. doi:10.3109/15376511003646440Marone PA, Lau FC, Gupta RC, et al. Safety and toxicological evaluation of undenatured type II collagen. Toxicol Mech Methods. 2010 May;20(4):175-89. doi:10.3109/15376511003646440Биологически активная добава к пище «ТРИО» товарного знака (т.з. «Хондрогард», ЗАО «ФармФирма «Сотекс» (СОГР АМ.01.06.01.003.R.000220.10.22 от 19.10.2022).Biologically active food supplement “TRIO” of the trademark (t.z. “Chondrogard”, CJSC “PharmFirma “Soteks” (СОГР AM.01.06.01.003.R.000220.10.22 dated 10/19/2022) (In Russ.).

The authors declare that there are no conflicts of interest present.